Navigation Links
Lymphoma Treatment May Harm, Halt Men's Sperm Production
Date:7/25/2014

FRIDAY, July 25, 2014 (HealthDay -- Treatment for lymphoma may lower men's fertility, new research indicates.

Both Hodgkin lymphoma and non-Hodgkin lymphoma, which are cancers of the body's white blood cells, often affect young people who are still in their reproductive years. For men, treatment for these cancers can harm or halt sperm production. Although most men regain their fertility within two years of treatment, the researchers cautioned that men should be counseled about the possibility of this significant side effect before treatment begins.

"While many men can look forward to their fertility returning after treatment is over, not all will be so fortunate," Dr. Rebecca Sokol, president of the American Society for Reproductive Medicine, said in a society news release. "It is imperative that prior to the initiation of therapy, counseling and sperm preservation be made available to all lymphoma patients and their partners who may want to have children in the future."

In conducting the study, the researchers monitored the sperm of lymphoma patients undergoing various treatments to determine how each therapy affected the men's fertility. Specifically, they examined the sperm of 57 Hodgkin lymphoma patients and 18 non-Hodgkin lymphoma patients who used a sperm bank before starting their cancer treatment.

The researchers analyzed the men's sperm before treatment began as well as at three months, six months, 12 months and 24 months after treatment ended. The patients' sperm were compared to the sperm of 257 healthy, fertile men.

Even before treatment, the sperm of the men with lymphoma were more damaged than that of their healthy peers. These levels of damage improved between three and six months after treatment, but were still worse than the men in the control group.

Depending on their diagnosis, the men received combination chemotherapy, with or without radiation. Following treatment, their sperm density, total count, motility and vitality dropped. The lowest levels occurred three and six months after treatment.

The study, published recently in the journal Fertility and Sterility, revealed that alkylating chemotherapy was more often associated with a total halt in sperm production or a longer period of time for sperm production to resume. Alkylating chemotherapy damages DNA as it attacks cancer cells, to keep the cells from reproducing.

For all the men who received non-alkylating chemotherapy, with or without radiation, sperm production recovered between 12 to 24 months after treatment ended.

Two years after treatment ended, the researchers noted that sperm production had not recovered for 7 percent of the men in the study.

More information

The American Cancer Society provides more information on lymphoma.

SOURCE: The American Society for Reproductive Medicine, news release, July 22, 2014

--


'/>"/>
Copyright©2014 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Protein may represent a switch to turn off B cell lymphoma
2. Researchers make promising discovery in pursuit of effective lymphoma treatments
3. New drug strategy attacks resistant leukemia and lymphoma
4. Mutations in JAK3 gene identified in subtype of lymphoma provide potential drug target
5. Limited Radiation May Help Some Kids With Lymphoma
6. Progress in quest to reduce use of radiation in treatment of pediatric Hodgkin lymphoma
7. New drug dramatically improves survival in Hodgkin lymphoma patients
8. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
9. New research seeks to improve survival for myeloma and lymphoma patients
10. Mayo Clinic completes first genome-wide analysis of peripheral T-cell lymphomas
11. Many options, good outcomes, for early-stage follicular lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lymphoma Treatment May Harm, Halt Men's Sperm Production
(Date:1/20/2017)... ... 2017 , ... Doctor C LLC, a company based out of Arizona that ... continue the marketing and distribution of its product, The Right C. , The Right ... absorption than traditional vitamin C supplements. At the trade show, Doctor C had the ...
(Date:1/20/2017)... ... , ... International Protein, a company based out of Australia that focuses on ... ECRM trade show in Hilton Head, SC. , International Protein was founded by ... line of products that would elevate her fitness regime. At this ECRM trade show, ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “Mary Magdalene: Grace ... mysterious life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is ... who spent her career as an educator interacting with countless women who had little ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... ... vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in a study ... Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive Expiratory Pressure ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “The Land ... brings attention to the issue of world hunger, and shares the simple and achievable ... Brubaker, devoted husband and member of the Fairview Missionary Church in Angola, Indiana where ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 The U.S. Food and ... Chronic Idiopathic Constipation (CIC) in adult patients. ... gastrointestinal disorders," said Julie Beitz , M.D., director of ... for Drug Evaluation and Research. "With the availability of new ... treatment for their condition." ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... , January 19, 2017 Incretin Mimetics/GLP-1 Agonists, ... Others The global anti-obesity drugs market is ... half of the forecast period and CAGR of 38.7% in the ... grow at a CAGR of 32.8% from 2016 to 2027. The ... 2021, and $24,063 million in 2027. ...
Breaking Medicine Technology: